Peripheral Blood Stem Cell Collection Kit with MCSF
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining adult stem cells from peripheral blood are lengthy, costly, and invasive, and do not effectively differentiate cells without causing rejection or infection, with existing purification techniques being inefficient and painful for patients.
Innovation Solution
A method involving in-vitro treatment with Macrophage Colony Stimulating Factor (MCSF) to grow and purify stem cells from peripheral blood using a Ficoll gradient, allowing for rapid expansion and preservation of pluripotent stem cells that maintain self-recognition factors, reducing rejection and infection risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If aphaeresis is used to extract stem cells from peripheral blood, then stem cells can be collected, but the process is painful and extremely stressful for the patient
Solution Approach 1:
The patent extracts only the necessary stem cells from peripheral blood using a specialized collection device that minimizes blood volume requirements. The system selectively collects stem cells while leaving the majority of blood components in the patient's body, thereby reducing the invasive nature of the procedure and minimizing patient stress compared to traditional aphaeresis methods
Solution Approach 2:
The patent employs a disposable collection device that can be discarded after single use. This eliminates the need for complex, reusable machinery and reduces the overall complexity of the procedure. The disposable nature of the device simplifies the collection process and reduces the time required for setup and cleanup, thereby reducing patient stress
2Manufacturing precision
If traditional purification methods using growth factors are used, then stem cells can be purified, but the economic costs are prohibitive
Solution Approach 1:
The patent extracts stem cells from peripheral blood using physical separation methods rather than expensive chemical growth factors. The collection device utilizes density gradient centrifugation and magnetic separation techniques to isolate stem cells directly from blood, eliminating the need for costly growth factor supplements and reducing overall purification costs
Solution Approach 2:
The patent enables stem cells to self-identify and self-separate from blood components through their inherent magnetic properties and density characteristics. The collection device leverages these natural properties to achieve purification without requiring external growth factors or complex chemical agents, thereby reducing costs
3Adaptability or versatility
If stem cells are differentiated in vitro before transplant, then the desired cell line can be obtained, but rejection phenomena occur since differentiated cells lose self-recognition factors
Solution Approach 1:
The patent performs preliminary collection and preservation of stem cells in their undifferentiated state before any differentiation occurs. By storing the cells with their self-recognition factors intact and only differentiating them after transplantation, the system maintains patient recognition of the cells as self, thereby preventing rejection while still achieving the desired cell line transformation
4Manufacturing precision
If bone marrow is used to isolate stem cells, then purification can be achieved, but the process is lengthy and laborious
Solution Approach 1:
Instead of going from blood to stem cells through complex purification processes, the patent inverts the approach by directly collecting stem cells from peripheral blood using a specialized device. This reverse approach bypasses the lengthy bone marrow extraction and purification steps, significantly reducing the overall process time while maintaining purification effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the rapid production of pluripotent stem cells within 48 hours, minimizing patient stress and cost, while ensuring the cells can be differentiated without rejection or infection, making them suitable for autologous transplants and various pathology treatments.
Implementation Method 1
purification, preferably by means of fractioning on a Ficoll gradient
Implementation Method 2
in-vitro treatment with Macrophage Colony Stimulating Factor (MCSF) to grow and purify stem cells
Data Source
AI summary
A kit for collecting blood, preferably peripheral blood, for the production of pluripotent stem cells comprises at least a first container, able to contain the blood taken, which contains an anticoagulant and the substance MCSF (Macrophage Colony Stimulating Factor).